Isomorphic Labs partner-led drug discovery

This go to market says Isomorphic is selling hard to replicate scientific output, not seats in a software dashboard. Large pharma buyers pay for teams that can take a target, run model driven design cycles, test compounds, and push programs toward a real drug candidate. That makes sales slower and more custom, but each deal can cover several targets, include research funding, milestones, and royalties, and expand after early validation, as Novartis did from three to up to six programs.

• The contract shape looks more like biotech partnering than SaaS. The initial Novartis deal covered three undisclosed small molecule targets, carried up to $1.2B in milestone payments plus tiered royalties, and the 2025 expansion added up to three more programs on the same terms.
  2 isomorphiclabs 3 goodwinlaw
• Isomorphic is being hired for the design loop itself. Lilly and Novartis started with small molecules, then the platform broadened into antibodies, peptides, and molecular glues, while J&J became the first cross modality deal. That supports deeper partner relationships instead of one product sold many times.
  1 sacra 4 isomorphiclabs
• This puts Isomorphic closer to Xaira and Genesis than to horizontal software vendors. Those companies also use partnerships and internal programs to turn proprietary data and experimental feedback into better models, while workflow platforms like Benchling sit more as infrastructure around the lab rather than owning molecule design outcomes.
  5 sacra 6 sacra 7 sacra

The next step is a gradual move from paid discovery partner to drug creation partner. If more collaborations expand across targets and modalities, Isomorphic can capture a larger share of pharma R&D budgets, while its owned pipeline gives it a path to keep even more of the value when its models produce clinically credible assets.